I'll research CVS ahead of their earnings. Let me gather recent filings, transcripts, and news.Let me read the most recent earnings materials and get more detailed news.Let me get the year-ago Q2 2025 results (the comparison base) and recent stock price/news context.Let me check recent analyst sentiment and consensus estimates.I have what I need. Let me compile the preview.# CVS Health (CVS) — Q2 2026 Earnings Preview
The single most important thing to understand going into this print is how much the narrative — and the stock — have already moved. CVS shares have re-rated dramatically in 2026, climbing roughly +30% year-to-date (from ~$80 in early January to ~$104–105 heading into the report), with the bulk of the move coming after the strong Q1 print on May 6, when the stock jumped from ~$81 to ~$87 and never looked back. Sentiment, per the latest news digest, has shifted strongly positive as management turnaround initiatives take hold, particularly in the managed care/Aetna business where price increases and the shedding of unprofitable plans are expected to improve the medical cost ratio.
The implication: the "cheap, broken, restructuring story" has become a "working turnaround" story. Expectations are no longer washed out. That raises the bar for Q2 — good results may be needed just to hold the stock, and the debate shifts from "can they stabilize?" to "how durable is the recovery and how much upside is left?"
Q1 2026 was a clear beat-and-raise:
Crucially, management flagged a roughly 60/40 first-half/second-half earnings split for 2026 — meaning the year is heavily front-loaded, and Q1 alone captured ~one-third of full-year AOI.
Year-ago base (Q2 2025): Adjusted EPS $1.81, adjusted operating income $3.81B, with segment AOI of HCB $1.31B, Health Services $1.58B, and Pharmacy & Consumer Wellness $1.34B. Note the prior-year quarter was messy on a GAAP basis — it absorbed $833M of litigation charges and a $471M Group Medicare Advantage premium deficiency reserve — so the YoY optics on reported figures will look distorted; focus on adjusted numbers and segment MBR.
Guidance-implied framework: Full-year AOI guidance midpoint (~$15.7B) at a 60/40 split implies ~$9.4B of H1 AOI; subtracting the $5.15B already booked in Q1 leaves ~$4.2–4.3B of implied Q2 AOI, roughly +12% YoY. Scaling off Q1's economics, that points to Q2 adjusted EPS comfortably above the $1.81 prior-year mark (framework math lands in the ~$1.90–2.10 area). The key takeaway: consensus is looking for solid year-over-year adjusted growth, driven almost entirely by the Aetna margin recovery.
This is the number that moves the stock. Full-year MBR is guided to 90.5% ± 50 bps, and the H2-weighted seasonality means the MBR steps up meaningfully from Q1's 84.6%. Investors will scrutinize: - The Q2 MBR vs. the year-ago 89.9% (which itself included ~140 bps from the PDR). - Whether current-year cost trend is behaving. Management has deliberately kept a "respectful and prudent" trend assumption and did not flow Q1's core outperformance into guidance. Any commentary that trend is landing better than feared would be a positive catalyst; any hint of reacceleration (a live risk across managed care in this cycle) would hit hard given the re-rated multiple. - Prior-year development and days claims payable. Q1 benefited from $1.1B of favorable PYD, and DCP rose to 42.9 days (from 38.9 at YE). Watch reserve adequacy — the market is sensitive to earnings "quality" (i.e., how much is core vs. reserve releases).
Given the strong Q1, the conservative embedded trend, and the front-loaded 60/40 shape, another guidance raise (or at least a raise-to-the-high-end) is plausible and arguably semi-expected. With the stock up 30%, a simple reiteration could disappoint. Watch how management frames the H2 setup.
Health Services AOI has been declining YoY (Q1 down 7%; Q2 2025 down 18%) on pharmacy client price improvements and rebate-guarantee pressure. Management says it's "executing well" against 2026 rebate-guarantee commitments with "no surprises" expected. Watch for confirmation the pressure is contained, plus updates on the shift toward net-cost/transparent models (TrueCost, CostVantage) and specialty/GLP-1 dynamics.
PCW has been a quiet outperformer (strong script volume, ~29% retail share, Rite Aid file acquisitions), though AOI has dipped YoY on reimbursement pressure and investments. Q1 was hurt by mild flu season and weather; a normalized comparison and script-volume trends are worth watching. FY guidance was nudged to at least $6.18B.
The most-asked forward question: when does the buyback come back on? Leverage improved to 3.84x at Q1, and management said share repurchase is not baked into 2026 guidance but is under evaluation as leverage improves. Any signal on resuming repurchases — or on M&A/capital deployment — could be a meaningful sentiment lever.
Look for early color on: - 2027 Medicare Advantage positioning — management reaffirmed a path to MA target margins (~3%) by 2028 and expects "meaningful progress" in 2027; the April Final Rate Notice was called "a step in the right direction" but still short of trend. - FTC settlement progress on PBM practices, and state-level PBM laws (Tennessee, effective mid-2028; potential legal action) — headline risk more than near-term numbers. - Health100 (the AI/Google Cloud consumer platform) launch progress — the strategic "consumer health-technology company" pivot.
CVS enters this print with momentum on its side but the easy money likely made. The bull case — a durable Aetna margin recovery, conservative embedded trend leaving room to beat, deleveraging opening the door to buybacks, and stabilizing PCW — is now substantially reflected in a stock up ~30% YTD. The bar for Q2 is a clean beat on adjusted EPS (vs. the $1.81 base), a well-behaved MBR, reassurance on medical cost trend, and ideally another guidance raise plus a credible path to resuming capital return. The primary downside risk is any crack in the cost-trend story or a "low-quality" beat leaning on reserve development — either of which the current valuation is less forgiving of than it was six months ago.
Note: EPS/AOI estimates above are derived from company guidance and the disclosed 60/40 first-half/second-half framework, not from formal published consensus, which I was unable to independently verify with the tools available.